WO2014041559A3 - Process for preparation of dabigatran etexilate and intermediates thereof - Google Patents
Process for preparation of dabigatran etexilate and intermediates thereof Download PDFInfo
- Publication number
- WO2014041559A3 WO2014041559A3 PCT/IN2013/000514 IN2013000514W WO2014041559A3 WO 2014041559 A3 WO2014041559 A3 WO 2014041559A3 IN 2013000514 W IN2013000514 W IN 2013000514W WO 2014041559 A3 WO2014041559 A3 WO 2014041559A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- dabigatran etexilate
- preparation
- intermediates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Abstract
Provided is a process for the preparation of dabigatran etexilate, a compound of Formula I or a salt thereof in a purity of at least 99.0% and wherein the level of compound of formula X and XV is less than 0.15% w/w relative to the amount of dabigatran etexilate, a compound of Formula I or a salt thereof, as determined by HPLC comprising (a) subjecting a crude compound of formula I to treatment with alkyl acetate and ketone to form a mixture; (b) optionally heating the mixture; and (c) isolating the compound of Formula I.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2481/MUM/2012 | 2012-08-27 | ||
IN2481MU2012 | 2012-08-27 | ||
US201261711663P | 2012-10-09 | 2012-10-09 | |
US61/711,663 | 2012-10-09 | ||
IN3260MU2012 | 2012-11-09 | ||
IN3260/MUM/2012 | 2012-11-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014041559A2 WO2014041559A2 (en) | 2014-03-20 |
WO2014041559A3 true WO2014041559A3 (en) | 2014-05-30 |
Family
ID=50278799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2013/000514 WO2014041559A2 (en) | 2012-08-27 | 2013-08-23 | Process for the preparation of dabigatran etexilate and intermediates thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014041559A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104974137A (en) * | 2014-04-04 | 2015-10-14 | 江苏天士力帝益药业有限公司 | New crystal forms of dabigatran etexilate mesylate and preparation method thereof |
CN103965164A (en) * | 2014-05-13 | 2014-08-06 | 南京生命能科技开发有限公司 | Dabigatran etexilate mesylate crystals VI and preparation method thereof |
CN103951654B (en) * | 2014-05-13 | 2016-08-24 | 南京生命能科技开发有限公司 | Crystal V of dabigatran etexilate methanesulfonate and preparation method thereof |
CN105461686A (en) * | 2014-08-25 | 2016-04-06 | 江苏豪森药业股份有限公司 | Preparation method of high purity Pradaxa crystal form |
CN105572275B (en) * | 2014-10-08 | 2017-09-29 | 华仁药业股份有限公司 | A kind of detection method of dabigatran etexilate methanesulfonate content |
CN104356111B (en) * | 2014-10-14 | 2017-12-26 | 蚌埠丰原医药科技发展有限公司 | A kind of method for preparing dabigatran etcxilate mesylate hydrolysis impurity |
CN105566296A (en) * | 2015-12-16 | 2016-05-11 | 蚌埠丰原医药科技发展有限公司 | Method for preparing dabigatran amidated impurities |
CN105859686B (en) * | 2016-05-24 | 2021-10-08 | 浙江华海药业股份有限公司 | Refining method of dabigatran etexilate free alkali |
CN106349221A (en) * | 2016-08-29 | 2017-01-25 | 常州市阳光药业有限公司 | Preparation method of high-purity dabigatran etexilate |
CN106916141A (en) * | 2017-04-06 | 2017-07-04 | 南京生命能科技开发有限公司 | A kind of preparation method of dabigatran etexilate methanesulfonate |
CN109975448B (en) * | 2017-12-28 | 2022-05-20 | 成都倍特药业股份有限公司 | Method for detecting related substances or/and content of dabigatran etexilate mesylate or preparation thereof |
CN110878083A (en) * | 2018-09-05 | 2020-03-13 | 连云港恒运药业有限公司 | Purification method of dabigatran etexilate intermediate |
CN117043150A (en) * | 2021-03-22 | 2023-11-10 | 天津睿创康泰生物技术有限公司 | New crystal form of dabigatran etexilate ethyl ester hydrochloride as well as preparation method and application thereof |
CN113307792A (en) * | 2021-05-21 | 2021-08-27 | 杭州国瑞生物科技有限公司 | Refining method of dabigatran etexilate and control method of specific degradation impurities of dabigatran etexilate |
CN115508479B (en) * | 2022-06-24 | 2023-07-07 | 常州制药厂有限公司 | Derivatization analysis method of n-hexyl chloroformate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037075A1 (en) * | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, their production and use as medicaments |
WO2010045900A1 (en) * | 2008-10-24 | 2010-04-29 | Zentiva, K.S. | A method for the preparation of dabigatran and its intermediates |
CN102050814A (en) * | 2009-11-06 | 2011-05-11 | 北京美倍他药物研究有限公司 | Ester derivatives of dabigatran |
WO2012077136A2 (en) * | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
-
2013
- 2013-08-23 WO PCT/IN2013/000514 patent/WO2014041559A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037075A1 (en) * | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, their production and use as medicaments |
WO2010045900A1 (en) * | 2008-10-24 | 2010-04-29 | Zentiva, K.S. | A method for the preparation of dabigatran and its intermediates |
CN102050814A (en) * | 2009-11-06 | 2011-05-11 | 北京美倍他药物研究有限公司 | Ester derivatives of dabigatran |
WO2012077136A2 (en) * | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
Also Published As
Publication number | Publication date |
---|---|
WO2014041559A2 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014041559A3 (en) | Process for preparation of dabigatran etexilate and intermediates thereof | |
SG10201808624VA (en) | Polymorphs of selinexor | |
IN2014MN02106A (en) | ||
WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
WO2013040286A3 (en) | Pharmaceutical compositions | |
WO2014043706A8 (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
IN2014MN01521A (en) | ||
JOP20120351B1 (en) | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | |
WO2012099942A3 (en) | Methods and compositions for treating metabolic syndrome | |
MX2015000965A (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes. | |
WO2012138147A3 (en) | 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof | |
WO2013014665A8 (en) | Intermediate compounds and process for the preparation of lurasidone and salts thereof | |
WO2013098836A8 (en) | A bis-quinophthalone pigment and a process for preparing the same | |
WO2012117357A3 (en) | Process for preparation of ketolide intermediates | |
WO2013111163A3 (en) | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof | |
TN2012000418A1 (en) | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | |
WO2013190455A3 (en) | Process for the preparation of lurasidone hydrochloride | |
WO2014003203A3 (en) | Method for producing stereoselective epoxyketone compound | |
IN2014MN00850A (en) | ||
MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
WO2012176061A8 (en) | Trpv1 antagonists including dihydroxy substituent and uses thereof | |
WO2015000900A3 (en) | Organic compounds | |
WO2014068333A3 (en) | New process | |
GB2523674A (en) | Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof | |
MX338556B (en) | Methods of isolating 4-chloro-2-fluoro-3-substituted-phenylboroni c acids. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13836773 Country of ref document: EP Kind code of ref document: A2 |